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Abstract
Objectives—Current treatment guidelines recommend immediate modification of antiretroviral
therapy in HIV infected individuals with incomplete viral suppression. These recommendations have
not been tested in observational studies or large randomized trials. We evaluated the consequences
of delayed modification following virologic failure.
Design/Methods—We used prospective data from two clinical cohorts to estimate the effect of
time until regimen modification following first regimen failure on all-cause mortality. The impact
of regimen type was also assessed. Since the effect of delayed switching can be confounded if subjects
with a poor prognosis modify therapy earlier than those with a good prognosis, we used a statistical
methodology—marginal structural models—to control for time-dependent confounding.
Results—A total of 982 subjects contributed 3414 person-years of follow up following first regimen
failure. Delay until treatment modification was associated with an elevated hazard of all-cause
mortality among subjects failing a reverse transcriptase inhibitor-based regimen (hazard ratio per
additional three months delay=1.23, 95% CI:1.08, 1.40), but appeared to have a small protective
effect among subjects failing a protease inhibitor-based regimen (hazard ratio per additional three
months delay=0.93, 95% CI: 0.87, 0.99).
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Conclusions—Delay in modification after failure of regimens that do not contain a protease
inhibitor is associated with increased mortality. Protease inhibitor-based regimens are less dependent
on early versus delayed switching strategies. Efforts should be made to minimize delay until treatment
modification in resource poor regions, where the majority of patients are starting reverse transcriptase
inhibitor-based regimens and HIV RNA monitoring may not be available.
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INTRODUCTION
Current treatment guidelines recommend careful monitoring of plasma HIV RNA levels during
antiretroviral treatment, with a goal of identifying virologic failure as early as possible and
modifying therapy once failure is confirmed.[1] The rationale for this recommendation is
twofold. First, ongoing viral replication can confer additional damage to a patient’s immune
system, most notably resulting in declining CD4+ T lymphocyte counts. Second, ongoing viral
replication in the presence of drug can favor the accumulation of additional resistance
mutations, potentially compromising future drug options.[2]
In practice, however, modification of a failing HAART regimen may be delayed as a result of
delayed detection of failure, sporadic follow-up, and/or lack of access to alternative regimens.
Access to HAART is being rapidly expanded in Africa and other resource poor settings where
the burden of HIV disease is the greatest.[3] The laboratory capacity and health care
infrastructure in many of these settings will not be able to support real-time monitoring of
plasma HIV RNA levels, suggesting the potential for substantial delays between treatment
failure and regimen modification.[4–8] Improved understanding of the long-term
consequences of delayed treatment modification is urgently needed to inform this scale-up.
While theoretical reasons suggest that delay until modification of a first-line failing regimen
should increase mortality, long-term data substantiating this claim are lacking. In addition,
there are reasons to think that the consequences of a delay until modification may differ if the
failing regimen contains a protease inhibitor drug as compared to a regimen that contains a
non-nucleoside reverse transcriptase inhibitor. Mutations conferring resistance to protease
inhibitors (particularly ritonavir-boosted protease inhibitors) generally do not emerge rapidly
during virologic failure, and when they do emerge do not inevitably result in cross-resistance
to the entire drug class.[9–14] Also, protease inhibitor resistance mutations result in a greater
reduction in viral fitness than do mutations conferring resistance to other drug classes.[15,
16] Perhaps as a result, failing HAART regimens containing a protease inhibitor are often able
to maintain stable CD4+ T lymphocyte counts.[17,18]
The most definitive manner in which to test the impact of early versus delayed switching on
long-term outcomes is to randomize patients to one of these two strategies. Such a study is not
feasible given current guidelines and the clear evidence that a delayed switch results in the
sequential accumulation of drug-resistance mutations. In the absence of a definitive
randomized study, prospectively collected observational data from well-established clinical
cohorts are needed. This approach, however, is problematic due to the presence of time
dependent confounding (confounding by indication). For example, disease progression over
the course of non-suppressive therapy, as reflected in CD4+ T lymphocyte counts, can
influence the decision when to modify failing therapy; thus subjects who delay modification
may disproportionately be those who progress more slowly, contributing to the appearance of
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a spurious protective effect from delayed switching. Standard statistical approaches are unable
to control for such confounding because prognostic factors over the course of non-suppressive
therapy may themselves be influenced by past exposure to failing therapy.[19]
Here, we used prospective cohort data to estimate the effect of delay until treatment
modification following first and second virologic HAART failures on hazard of mortality, and
how this effect differed between common first line therapeutic regimens. Immunologic failure
was considered as a secondary outcome. We employed a statistical methodology—marginal
structural models—that allows for control of time-dependent confounding.[20] The utility of
this approach has been demonstrated in HIV-related and other applications.[21–25]
METHODS
Study design and participants
Two prospective cohort studies contributed data for the analysis. The Johns Hopkins HIV
Clinical Cohort (JHHCC) and University of North Carolina HIV Clinical Cohort (UNCHCC)
are longitudinal observational studies of patients receiving primary HIV care in the Baltimore,
MD area and through the UNC HIV Clinic, respectively. In both cohorts, after informed
consent, information is collected in person by trained medical record technicians and
electronically from a variety of sources.
To be eligible for this analysis, patients must have initiated their first HAART regimen while
under observation and have subsequently experienced virologic failure. HAART was defined
as any of the following: (1) any regimen containing four or more antiretroviral drugs; (2) any
three drug regimen including drugs from two or more therapeutic drug classes; (3) any regimen
containing a ritonavir-boosted protease inhibitor; or, (4) a triple nucleoside reverse
transcriptase inhibitor (NRTI) regimen containing zidovudine/lamivudine/abacavir or
zidovudine/lamivudine/tenofovir.
Virologic failure was defined as two consecutive HIV RNA levels above a time-dependent
threshold; the second viral load had to occur after week 16. Between weeks 12 and 24, the
threshold for failure was defined as 1000 copies RNA/ml, while after week 24 a threshold of
500 copies RNA/ml was used. HAART failures occurring between February 1996 and May
2006 were included.
The exposure of interest was time until modification of the failing regimen. Modification was
defined as the initiation of a new HAART regimen containing either a new drug class or at
least two drugs not used in the failing regimen. Subjects were censored if they interrupted rather
than modified their original failing regimen.
The primary endpoints were time to either (1) all cause mortality or (2) a composite of all cause
mortality and immunologic failure, where immunologic failure was defined as either two
consecutive CD4+ T lymphocyte counts or two CD4 counts within any 12 week period below
the pre-HAART CD4 level (this latter endpoint has been used by our group in prior studies
[18] and is discussed in the DHHS treatment guidelines[26]).
Statistical analyses
All eligible patients were included in the primary analysis. We also performed two sets of
supplementary analyses, in which subjects were excluded if they a) failed a protease inhibitor
regimen that was not ritonavir-boosted, or b) had received antiretroviral therapy prior to
initiating HAART. Analyses were also repeated among the subset of individuals who
experienced a second episode of virologic failure, treating time of second failure as baseline.
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The following lab measurements were treated as time-varying confounders: CD4+ T
lymphocyte count, nadir CD4 count, CD4%, plasma HIV RNA level, peak HIV RNA level.
Longitudinal data on past and current antiretroviral treatment were summarized, respectively,
as the number of drugs in each class experienced in the past, and the number of drugs in each
class and total number of classes in the current regimen. Calendar date was considered as an
additional time-varying covariate. Baseline and demographic covariates included sex, age,
race, injection drug use, men having sex with men, date of first HAART, and history of
antiretroviral use pre-HAART. Analyses of UNCHCC also included CD8+ T lymphocyte
counts and CD8%, diagnosis of an AIDS-defining illness, and HIV diagnosis date, while
JHHCC included date of first antiretroviral use. This same set of baseline and time-dependent
covariates were examined as potential predictors of censoring, regimen modification, and
treatment interruption.
Data were analyzed on a discrete monthly time scale, beginning at time of confirmed virologic
failure. Values of time-varying covariates reflected the most recent measurement available on
the last day of the month. All time-varying covariates were lagged by one month when
controlling for confounding to ensure that confounder values preceded any treatment decision.
Marginal structural model analyses aimed to replicate the results of a trial in which subjects
experiencing HAART failure were assigned to remain on their failing therapy for a random
duration before switching to a new HAART regimen.[19,20,24] Estimation was based on
inverse probability of treatment weighting. Under this approach, subjects were assigned
weights inversely proportional to their probability of having received their observed treatment
histories given their covariates. A re-weighted population was thus created, in which treatment
groups were balanced with respect to covariate distributions, and a weighted Cox (or pooled
logistic regression) model was fit. Inverse probability weights were used to control for
confounding of the delay until modification, potential bias as a result of informative censoring
and treatment interruption, and baseline differences between subjects whose failing regimen
did versus did not contain a protease inhibitor. [20] All weights were stabilized.
Models for the weights were fit using logistic regression, where model selection was based on
the Deletion/Substitution/Addition algorithm and 5-fold cross validation [27], a flexible
approach that allows for data-adaptive selection of non-linear covariate effects, interactions
between covariates, and variation over time. All models used in the weights were estimated
separately for the two cohorts, allowing for heterogeneity in the way in which covariates were
used to make treatment decisions, how the probability of censoring and interruption depended
on covariates, and the distribution of covariates between subjects failing protease inhibitor vs.
reverse transcriptase inhibitor regimens. Sensitivity analyses were performed using several
alternative weight models.
Following estimation of weights, the cohorts were pooled to yield effect estimates. In our
primary analyses we employed a weighted pooled logistic regression model that included time
spent on failing therapy and elapsed time since failure as main terms. We also employed several
flexible approaches to modeling the conditional hazard of mortality, including weighted data-
adaptive regression using the D/S/A algorithm. Standard error estimates were based on non-
parametric bootstrap sampling.
RESULTS
A total of 608 subjects in the JHHCC and 374 subjects in the UNCHCC experienced at least
one virologic failure while on HAART. Together, these 982 subjects contributed a total of 3414
person-years of follow-up, with a median of 36.5 months per person (IQR: 12.0, 70.0). Seven
hundred and forty two (76%) of first HAART failures occurred among subjects treated with
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at least one protease inhibitor drug; of these, 234 (32%) received a ritonavir-boosted protease
inhibitor. The majority of the remaining patients (225/240, 94%) were on a non-nucleoside
reverse transcriptase inhibitor (NNRTI)-based regimen; of these, 163 (72%) received
efavirenz.
All 982 subjects contributed to analyses until they were censored, (administratively or due to
loss to follow up), interrupted therapy, or died, whichever happened first. Modification of the
failing regimen was observed in 567 subjects (58%) following first HAART failure; the
remaining subjects interrupted treatment (N=286, 29%), died (N=6, 1%), or were censored
(N=123, 13%) before modifying therapy. Subjects for whom a treatment switch was observed
waited a median of 8 months following failure before modifying therapy (IQR: 3, 19).
There were 93 deaths and 243 immunologic failures. The crude mortality rate was equivalent
(2.7 deaths per 100 person-years) among subjects who failed a protease inhibitor-based
regimen and those who failed a reverse transcriptase inhibitor regimen. The crude immunologic
failure rates were 7.8 failures per 100 person years and 10.3 failures per 100 person years for
protease inhibitor and reverse transcriptase inhibitor based regimens, respectively. Three
hundred fifty five subjects also experienced a second HAART failure. These subjects were
observed for a total of 1014 years of person time following second HAART failure (median
30 months of follow up per person; IQR: 20, 55). A total of 36 deaths and 107 immunologic
failures were observed following second HAART failure.
Compared to subjects failing a reverse transcriptase inhibitor regimen, those subjects whose
failing regimen contained a protease inhibitor failed their first HAART regimen at an earlier
calendar date (P<0.001), were more likely to have used antiretroviral drugs prior to starting
HAART (P<0.001), were on regimens containing fewer nucleoside reverse transcriptase
inhibitors at time of failure (P<0.001), and had lower nadir CD4+ T lymphocyte counts and
lower CD4 counts at time of failure (Table 1). Mean plasma HIV RNA level measured prior
to regimen modification was 3.54 log10 copies/ml among regimens that contained a protease
inhibitor, and 3.70 log10 copies/ml among regimens that did not contain a protease inhibitor
(P=0.14).
Subjects were more likely to modify treatment after their first failure of HAART if their most
recent and nadir CD4+ T lymphocyte counts were lower, and if their most recent HIV RNA
level was higher (Table 2). In the JHHCC, subjects were less likely to modify if they remained
on regimens with more drugs, more drug classes, or with ritonavir boosting. In the UNCHCC,
subjects diagnosed with an AIDS-defining illness ever or within the last month were more
likely to modify therapy. Similar associations were found following second HAART failures
(data not shown).
Effect of time to modification on mortality and immunologic failure
Among patients with a first HAART failure on a reverse transcriptase inhibitor-based regimen,
a 3-month delay until treatment modification was associated with an elevated hazard of
mortality and immunologic failure (HR=1.23; 95% CI 1.08, 1.40; P=0.002 for death and
HR=1.21; 95% CI 1.07, 1.36; P=0.002 for immunologic failure) (Table 3). In comparison,
among patients failing a protease inhibitor-based first HAART regimen, a 3-month delay until
treatment modification slightly reduced the hazard of mortality (HR=0.93; 95% CI 0.87, 0.99;
P=0.03 for death and HR=0.98; 95% CI 0.94, 1.03; P=0.45 for immunologic failure); however,
this weak association should be interpreted cautiously given the multiple comparisons
performed. These findings were reasonably consistent across cohorts and following second
HAART failures (Figure 1).
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Secondary and sensitivity analyses
Supplementary analyses using alternative approaches to estimate the weights and excluding
subjects on protease inhibitor-based regimens that did not include ritonavir boosting did not
substantively alter findings (data not shown). Following exclusion of subjects with
antiretroviral experience prior to initiating HAART, 187 failures on a protease inhibitor-based
regimen and 127 failures on a reverse transcriptase inhibitor-based regimen were analyzed.
Estimated hazard ratios associated with a 3 month delay in treatment modification among this
subgroup were generally consistent with results of the primary analysis, although they no longer
achieved statistical significance (among reverse transcriptase inhibitor-based failures: HR for
death=1.17, 95% CI: 0.70, 1.93; HR for immunologic failure=1.07, 95%CI: 0.85, 1.35; among
protease inhibitor-based failures: HR for death=0.93, 95%CI: 0.69, 1.24; HR for immunologic
failure=0.95, 95%CI: 0.85, 1.05). The relationship between delay until modification and hazard
of mortality over time was further investigated using several alternative modeling approaches
to allow for data –adaptive selection of interactions between terms and nonlinear contributions
of delay until modification and elapsed time since failure (Figure 2).
DISCUSSION
Current antiretroviral treatment guidelines recommend modifying therapy as soon as virologic
failure is confirmed, particularly following first and second HAART failure. This
recommendation is based primarily on well-accepted theoretical principles, but has not been
rigorously addressed in either observational studies or large randomized clinical trials. Here,
we applied a robust analytic technique that accounts for time-dependent confounding to two
large prospective clinic-based cohorts, and found that among patients failing a reverse
transcriptase inhibitor-based regimen (the vast majority of which were receiving a NNRTI and
two nucleoside analogues), delay until treatment modification following virologic failure
increased the hazard of both long-term mortality and immunologic failure. There was no clear
harm associated with a delayed modification after failure of a protease inhibitor-based regimen.
These observations were stable when we limited our analysis to those who were treatment
naïve prior to their first HAART regimen and when we limited our analysis to those whose
protease inhibitor regimen included ritonavir boosting.
Data-adaptive regression was used to explore how the hazard of mortality changed over time
under various switch times. Following first HAART failure on a reverse transcriptase inhibitor
regimen, the hazard of mortality increased sharply while the patient remained on his or her
original failing therapy. The hazard of mortality plateaued following regimen modification,
but remained elevated for up to 4 years among subjects who delayed switching. This finding
is consistent with the two hypothesized mechanisms by which delayed modification increases
mortality: 1) ongoing viral replication contributes to immune depletion and increased mortality
risk while subjects remain on their non-suppressive therapy; and, 2) delay of modification
results in accumulation of additional resistance mutations, with long term consequences for
treatment options.
In contrast, we observed no harm from delaying modification of a regimen containing a
protease inhibitor drug following first and second HAART failures. Data-adaptive regression
supported a distinct pattern in the hazard of mortality over time in this group (as compared to
subjects failing a reverse transcriptase inhibitor regimen). Following first HAART failure on
a protease inhibitor regimen, the hazard of mortality increased over time, with very little short-
term difference between subjects who modified therapy immediately and those who delayed
modification. To the extent that the hazard of mortality differed among subjects with immediate
versus delayed modification times, a protective effect of delayed modification emerged only
several years following failure.
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Several mechanisms may account for the lack of harm in delaying modification after failure
of a protease inhibitor regimen. First, earlier work has shown that resistance emerges rapidly
during failure of an NNRTI-based regimen but is uncommon after failure of most protease
inhibitor-based regimens.[9–14] Second, during first and second HAART failure, cross-
resistance among the protease inhibitors is less common than it is among the NNRTI class.
Hence, patients who develop resistance to the protease inhibitor component of their regimen
may still be able to respond to other drugs in this class. A third and more speculative mechanism
pertains to the virulence of protease inhibitor resistant viruses. Failure of a protease inhibitor
regimen has been associated with less rapid immunologic progression than failure of an NNRTI
regimen.[17,28] This effect may be due both to reduced HIV RNA levels and to a reduced
capacity of the protease inhibitor-resistant HIV variant to cause CD4+ T cell decline in vivo.
[29,30] Our observations suggesting differential long-term outcomes based on regimen type
(NNRTI versus protease inhibitor) are supported by research showing that NNRTI resistance
is a more consistent predictor of mortality than resistance to other therapeutic drug classes.
[25,31] Collectively, these observations indicate that protease inhibitor-based regimens will
be associated with lower rates of disease progression than NNRTI-based regimens in situations
where modification is delayed because virologic failure cannot be identified (due to lack of
plasma HIV RNA monitoring) or because subsequent regimens are not available.
Given the observational nature of the data, unmeasured confounders may have biased results
in an unpredictable direction. Importantly, however, both the JHHCC and UNCHCC included
laboratory data collected at the discretion of the clinician, providing access to important factors
that affect treatment decisions. Additional bias could have resulted from misspecification of
the models used to estimate the weights. In order to minimize this concern, we used flexible
data-adaptive approaches in modeling the weights, and performed sensitivity analyses
considering alternative weight models. These additional analyses yielded consistent results,
supporting the robustness of our findings.
Several factors should be taken into account when considering the extent to which our results
can be generalized. First, detection of virologic failure, which determined time of eligibility
for our sample, depended on the measurement of consecutive HIV RNA levels. Thus, virologic
failure could be identified more rapidly among subjects who had HIV RNA levels assessed
more frequently. Similarly, detection of immunologic failure depended on the timing of CD4
+ T cell count measurements. In addition, a substantial proportion of our sample consisted of
subjects treated with non-boosted protease inhibitor regimens and of subjects with exposure
to antiretroviral drugs prior to initiating HAART, potentially limiting the applicability of our
results to inform expanded access to HAART in treatment-naïve settings. To investigate the
latter issue, we performed sensitivity analyses in which we excluded, in turn, subjects treated
with non-boosted protease inhibitors and subjects with antiretroviral experience prior to
initiating HAART. While the reduced sample sizes meant that the variability of our estimates
increased such that the results were no longer significant, the consistency of the point estimates
across these subpopulations suggests that the findings reported here are not solely the result of
historical treatment patterns experienced by these observational cohorts.
Although we report here no clear harm to delaying a switch in therapy among protease inhibitor-
treated patients, it should be emphasized that the optimal long-term clinical outcome was
observed among those who were treated with reverse transcriptase inhibitor regimens (most
of whom were on standard NNRTI/nucleoside analog regimens) and who were managed
aggressively during virologic failure. In other words, there was a hierarchy of efficacy in the
context of first HAART failure: subjects failing a reverse transcriptase inhibitor regimen who
modified immediately had the lowest mortality, followed by subjects failing a protease
inhibitor regimen at a range of switch times, and finally, subjects failing a reverse transcriptase
inhibitor regimen who delayed modification had the highest mortality.
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In summary, our findings support the recommendation that treatment be modified immediately
following first HAART failure. This is particularly true for individuals receiving a standard
first HAART regimen containing nucleoside analogues and a NNRTI. Access to HAART is
being expanded rapidly worldwide, and, at least in the short term, first HAART regimens are
likely to be NNRTI-based. Given the elevated risk of mortality that is associated with delayed
treatment modification in patients receiving these regimens, our data support making viral load
testing more available. Our data also suggest that the prolonged treatment benefits that have
been repeatedly observed during virologic failure—all of which have been based largely on
protease inhibitor regimens—may not be realized in regions where access to these regimens
is limited.[17,18,32,33] These considerations should be taken into account when planning
HAART delivery systems, and within the context of resource constraints and the urgent need
to scale-up therapy as rapidly as possible, efforts should be made to minimize delay until
modification.
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Conditional hazard ratios estimated using weighted pooled logistic regression, with weights
used to control for confounding of time until treatment modification, baseline differences
between subjects failing a protease inhibitor vs. reverse transcriptase inhibitor regimen, and
potentially informative censoring. Hazard ratios for reverse transcriptase inhibitor regimens in
the UNCHCC following 2nd HAART failure not reported due to small sample size (N=31). PI:
failing regimen contains protease inhibitor; Non-PI: failing regimen does not contain protease
inhibitor; Death: endpoint is all-cause mortality; CD4 failure: endpoint is composite of all-
cause mortality and immunologic failure; JHHCC 1st failure/JHHCC 2nd failure: among
subjects in JHHCC experiencing first and second HAART failures, respectively; UNC 1st
failure/UNC 2nd failure: among subjects in UNCHCC experiencing first and second HAART
failures, respectively.
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Conditional hazard of mortality over time, plotted for a range of delay times until treatment
modification. Estimates based on weighted pooled logistic regression, with weights used to
control for confounding of time until treatment modification, baseline differences between
subjects failing a protease inhibitor vs. reverse transcriptase inhibitor regimen, and potentially
informative censoring. The Deletion/Substitution/Addition algorithm was used to model the
conditional hazard of all-cause mortality as a function of time since failure occurred and months
spent on failing regimen, making minimal parametric assumptions. A. Among subjects failing
a protease inhibitor regimen. B. Among subjects failing a reverse transcriptase inhibitor
regimen.
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